Similarly, inhibitors of focal adhesion kinase (FAK), a key regulator of integrin signaling, target tumor cell proliferation, invasion, metastasis, and angiogenesis and are promising drugs for combination therapy—in melanoma with BRAFi and in other tumors such as CRC with activated stroma—because of a limitation of tumor cell escape mechanisms [22,23]. This evidence concerns the gene PTK2 and neoplasm.